Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/96426
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Domschke, K. | - |
dc.contributor.author | Tidow, N. | - |
dc.contributor.author | Schwarte, K. | - |
dc.contributor.author | Ziegler, C. | - |
dc.contributor.author | Lesch, K. | - |
dc.contributor.author | Deckert, J. | - |
dc.contributor.author | Arolt, V. | - |
dc.contributor.author | Zwanzger, P. | - |
dc.contributor.author | Baune, B. | - |
dc.date.issued | 2015 | - |
dc.identifier.citation | Journal of Neural Transmission, 2015; 122(1):99-108 | - |
dc.identifier.issn | 0300-9564 | - |
dc.identifier.issn | 1435-1463 | - |
dc.identifier.uri | http://hdl.handle.net/2440/96426 | - |
dc.description | First online: 10 May 2014 | - |
dc.description.abstract | The monoamine oxidase A (MAO-A) gene has been suggested to be involved in the pathogenesis as well as the pharmacological treatment of major depressive disorder. In the present analysis, for the first time a pharmacoepigenetic approach was applied investigating the influence of DNA methylation patterns in the MAO-A regulatory and exon1/intron1 region on antidepressant treatment response. 94 patients of Caucasian descent with major depressive disorder (f = 61; DSM-IV) were analyzed for DNA methylation status at 43 MAO-A CpG sites via direct sequencing of sodium bisulfite treated DNA extracted from blood cells. Patients were also genotyped for the functional MAO-A VNTR. Clinical response to antidepressant treatment with escitalopram was assessed by intra-individual changes of HAM-D-21 scores after 6 weeks of treatment. Apart from two CpG sites, male subjects showed no or only very minor methylation. In female patients, lower methylation at two individual CpG sites in the MAO-A promoter region was nominally associated with impaired response to antidepressant treatment after 6 weeks (GRCh37/hg19: CpG 43.514.063, p = 0.04; CpG 43.514.684, p = 0.009), not, however, withstanding correction for multiple testing. MAO-A VNTR genotypes did not influence MAO-A methylation status. The present pilot data do not suggest a major influence of MAO-A DNA methylation on antidepressant treatment response. However, the presently observed trend towards CpG-specific MAO-A gene hypomethylation-possibly via increased gene expression and consecutively decreased serotonin and/or norepinephrine availability-to potentially drive impaired antidepressant treatment response in female patients might be worthwhile to be followed up in larger pharmacoepigenetic studies. | - |
dc.description.statementofresponsibility | Katharina Domschke, Nicola Tidow, Kathrin Schwarte, Christiane Ziegler, Klaus-Peter Lesch, Jürgen Deckert, Volker Arolt, Peter Zwanzger, Bernhard T. Baune | - |
dc.language.iso | en | - |
dc.publisher | Springer-Verlag | - |
dc.rights | © Springer-Verlag Wien 2014 | - |
dc.source.uri | http://dx.doi.org/10.1007/s00702-014-1227-x | - |
dc.subject | Monoamine oxidase A; Epigenetics; Pharmacoepigenetics; Methylation; Depression; Gender | - |
dc.title | Pharmacoepigenetics of depression: no major influence of MAO-A DNA methylation on treatment response | - |
dc.type | Journal article | - |
dc.identifier.doi | 10.1007/s00702-014-1227-x | - |
pubs.publication-status | Published | - |
dc.identifier.orcid | Baune, B. [0000-0001-6548-426X] | - |
Appears in Collections: | Aurora harvest 7 Psychiatry publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.